Matej Patzelt, Lucie Zarubova, Adrianna Brandejsova, Pavel Klener, Marek Trneny, Josef Barta, Kamila Benkova, Robert Gurlich and Andrej Sukop
Royal Vinohrady Teaching Hospital, Czech Republic Charles University, Czech Republic Institute of Pathological Physiology First Faculty of Medicine-Charles University, Czech Republic AeskuLab Pathology Czech Republic
Posters & Accepted Abstracts: Arch Cancer Res
Breast implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare peripheral T-cell lymphoma. BIA-ALCL is a disease of the fibrous capsule surrounding the implant and occurs in patients after both breast reconstruction and augmentation. More than 300 cases have been reported so far. Here, we present the first case of BIA-ALCL in a transgender patient. In 2007, a 33 year-old transgender male to female underwent bilateral breast augmentation as a part of his transformation to female. In June 2014, the patient developed a 5 cm tumorous mass in the lower inner quadrant of her left breast. Magnetic resonance of the chest revealed a ruptured implant and a tumorous mass penetrating into the capsule and infiltrating the pectoral muscle. Radical resection (R0) surgery was performed and the implant, silicone gel and capsule were removed and the tumorous mass was resected together with a part of the pectoral muscle. Histology revealed anaplastic large cell lymphoma, ALK1-negative. The patient underwent standard staging procedures for lymphoma including a PET-CT scan and a bone marrow trephine biopsy, which confirmed stage IE. The patient was treated with the standard chemotherapy for systemic ALCL-6 cycles of CHOP-21 (cyclophosphamide, vincristine, doxorubicin and prednisone). Final PET-CT restaging revealed complete remission of the disease. The patient was tumor-free at the 2-year follow-up. So far, breast implant-associated ALCL has been reported only in women who received implants for either reconstructive or aesthetic augmentation. This is the first report of BIA-ALCL in a transgender person.
E-mail: